ArticleInternational journal of endocrinology and metabolism2027
Association Between Serum Amylin, Irisin, and Sirtuin 1 in Male Patients with Type 2 Diabetes and Diabetic Nephropathy.
Article in International journal of endocrinology and metabolism, 2027. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Type 2 diabetes mellitus (DM) is a progressive disease worldwide that leads to various complications. Given the roles of the hormones amylin and irisin and the enzyme sirtuin 1 (SIRT1) in metabolism and oxidative stress, we focused on these parameters in the serum of patients. Objectives: We investigated the associations between serum amylin, irisin, and SIRT1 levels and diabetic nephropathy (DN), an important complication of DM. Methods: Patients with DM (n = 50) and DN (n = 50) were included in this single-center cross-sectional study. Various parameters were measured from fasting blood and urine samples. Serum amylin, irisin, and SIRT1 levels were measured using enzyme-linked immunosorbent assay kits. In addition to demographic characteristics, fasting blood sugar, glycated hemoglobin, serum insulin, urine creatinine, and estimated glomerular filtration rate were used to classify participants. Results: After adjustment for age, diabetes duration, body mass index, fasting blood sugar, glycated hemoglobin, homeostasis model assessment of insulin resistance, triglycerides, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol, amylin levels were significantly lower, whereas irisin and SIRT1 levels were significantly higher, in the DN group than in the DM group. Multivariable logistic regression showed that higher amylin levels were associated with lower odds of DN, whereas higher irisin and SIRT1 levels were associated with higher odds of DN. Receiver operating characteristic curves were used to evaluate the ability of these biomarkers to discriminate between the DM and DN groups. In addition, mediation analysis showed associations among irisin, SIRT1, and DN. Conclusions: These findings suggest that irisin and SIRT1 are associated with DN status in patients with diabetes and may provide insights into metabolic complications. However, longitudinal studies are needed to establish causality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.